

## **Supplementary Materials**

### **Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics**

**Jürgen B. Bulitta, Yuanyuan Jiao, Cornelia B. Landersdorfer, Dhruvitkumar S. Sutaria, Xun Tao, Eunjeong Shin, Rainer Höhl, Ulrike Holzgrabe, Ulrich Stephan and Fritz Sörgel**


**Table 1.** Estimates from the original dataset compared to the median and 95% confidence intervals from nonparametric bootstrapping (200 replicates) for the final population PK model.

| PK Parameters  | Symbol                | Unit | Population Mean    |   | Between Subjects Variability (CV) |   |
|--|-----------------------|------|--------------------|---|-----------------------------------|---|
|  |                       |      | Original Dataset   | Median (95% CI)<br>(2.5 <sup>th</sup> to 97.5 <sup>th</sup> percentile) | Original Dataset                  | Median (95% CI)<br>(2.5 <sup>th</sup> to 97.5 <sup>th</sup> percentile) |
| Pefloxacin   |                       |      |                    |   |                                   |   |
| Oral bioavailability                                       | F <sub>BIO</sub>      | -    | 1.00 <sup>a</sup>  | 1.01 (0.909–1.11) <sup>a</sup>  | 0.146 <sup>a</sup>                | 0.140 (0.0548–0.210) <sup>a</sup>                                       |
|  |                       |      | 1.03 <sup>b</sup>  | 1.03 (0.934–1.10) <sup>b</sup>  | 0.127 <sup>b</sup>                | 0.119 (0.0478–0.160) <sup>b</sup>                                       |
| Absorption lag-time  | T <sub>lag</sub>      | min  | 13.3               | 13.4 (12.8–14.1)  | 0.0712                            | 0.0631 (0.0261–0.0867)  |
| Absorption half-life                                       | T <sub>abs</sub>      | min  | 19.8 <sup>a</sup>  | 20.2 (9.65–45.1) <sup>a</sup>   | 1.10 <sup>a</sup>                 | 1.01 (0.627–1.35) <sup>a</sup>  |
|  |                       |      | 11.2 <sup>b</sup>  | 11.3 (6.20–18.1) <sup>b</sup>   | 0.983 <sup>b</sup>                | 0.969 (0.518–1.34) <sup>b</sup>   |
| Reabsorption half-life from intestine                      | T <sub>reabs</sub>    | min  | 65.4 <sup>a</sup>  | 65.5 (41.0–89.7) <sup>a</sup>   | 0.334 <sup>a</sup>                | 0.0720 (0.00768–0.600) <sup>a</sup>                                     |
|  |                       |      | 20.8 <sup>b</sup>  | 20.0 (6.37–41.8) <sup>b</sup>   | 0.804 <sup>b</sup>                | 0.747 (0.0965–1.27) <sup>b</sup>  |
| Volume of distribution for central comp.                   | V <sub>1</sub>        | L    | 40.8               | 39.8 (22.2–58.6)  | 0.435                             | 0.417 (0.0313–0.632)  |
| Volume of distribution for peripheral comp.                | V <sub>2</sub>        | L    | 65.4               | 66.6 (50.2–76.7)  | 0.131                             | 0.0619 (0.00851–0.309)  |
| Non-renal clearance  | CL <sub>NR</sub>      | L/h  | 8.56               | 8.59 (7.44–9.77)  | 0.238                             | 0.224 (0.125–0.310)   |
| Renal clearance  | CL <sub>R</sub>       | L/h  | 0.705              | 0.710 (0.662–0.753)   | 0.168                             | 0.166 (0.0111–0.265)  |
| Distribution clearance                                     | CL <sub>D</sub>       | L/h  | 406                | 414 (164–1,199)   | 1.19                              | 1.18 (0.693–2.05)   |
| Disease factor for nonrenal clearance                      | F <sub>CYF, NR</sub>  | -    | 0.861              | 0.850 (0.694–1.07)  | 0.05                              | fixed   |
| Disease factor for renal clearance                         | F <sub>CYF, R</sub>   | -    | 1.53               | 1.53 (1.21–1.78) <sup>c</sup>   | 0.05                              | fixed   |
| Disease factor for volume of distribution                  | F <sub>CYF, VSS</sub> | -    | 0.916              | 0.931 (0.739–1.15)  | 0.05                              | fixed   |
| Maximum rate of exsorption                                 | CL <sub>gut</sub>     | L/h  | 66.0               | 66.0 (fixed)  | 0                                 | fixed   |
| Plasma conc. associated with half-maximal V <sub>MEX</sub> | K <sub>MEX</sub>      | mg/L | 1.44               | 1.50 (0.711–2.50)   | 0.1                               | fixed   |
| Norfloxacin  |                       |      |                    |   |                                   |   |
| Formation fraction   | fm <sub>NOR</sub>     | -    | 0.201 <sup>a</sup> | 0.198 (0.168–0.239) <sup>a</sup>  | -                                 | -   |
|  |                       |      | 0.174 <sup>b</sup> | 0.172 (0.162–0.185) <sup>b</sup>  |                                   |   |
| Pefloxacin-N-oxide   |                       |      |                    |   |                                   |   |
| Formation fraction   | fm <sub>NOX</sub>     | -    | 0.244 <sup>a</sup> | 0.247 (0.220–0.271) <sup>a</sup>  | -                                 | -   |
|  |                       |      | 0.178 <sup>b</sup> | 0.180 (0.167–0.190) <sup>b</sup>  |                                   |   |


<sup>a</sup> Parameter estimates for patients with CF.

<sup>b</sup> Parameter estimates for healthy volunteers. When only one line of parameter estimates is reported, the same estimate was used in patients with CF and healthy volunteers.

<sup>c</sup> Significantly different from 1.0 ( $p < 0.05$ ; two-sided test) based on 200 bootstrap replicates.



**Figure S1.** Observed vs. individual fitted plasma concentrations (top) and fractions of dose excreted in urine (rows 2 to 4) on linear (left side) and logarithmic scale (right side). The green line represents the line of identity and the dashed blue line a LOESS smoother.



**Figure S2.** Observed vs. population fitted plasma concentrations (top) and fractions of dose excreted in urine (rows 2 to 4) on linear (left side) and logarithmic scale (right side). The green line represents the line of identity and the dashed blue line a LOESS smoother.

```

1  $PROJECT THIS WILL BE A TERRIFIC PROJECT
2
3  $DIFFEQ_DIF
4
5  GUT      = X(1)
6  DC1      = X(2)/V1_COV
7  DC2      = X(3)/V2_COV
8  URI      = X(4) ; Amount of pefloxacin          in urine
9  URINO    = X(5) ; Amount of norfloxacin         in urine
10 URIDE    = X(6) ; Amount of pefloxacin-N-oxide in urine
11 GUTEHC   = X(7)
12
13 TPD = MOD(T,72)
14
15 IF (TPD.GT.TLAGH) THEN
16   KAT = KA
17 ELSE
18   KAT = 0
19 ENDIF
20
21 CLMM = CLgut_COV*KM / (KM+DC1)
22
23 XP(1) = - KAT*GUT
24 XP(2) = R(1) + KAT*GUT - CLR_COV*DC1 - CLNR_COV*DC1 - CLMM*DC1 - CLD_COV*DC1 + CLD_COV*DC2 + KAEHC*GUTEHC
25 XP(3) = CLD_COV*DC1 - CLD_COV*DC2
26
27 XP(4) = CLR_COV*DC1
28 XP(5) = FM_NOR*CLNR_COV*DC1
29 XP(6) = FM_NOX*CLNR_COV*DC1
30
31 XP(7) = + CLMM*DC1 - KAEHC*GUTEHC
32
33 $OUTPUT_GLB
34
35 IF (GRP.EQ.1) THEN
36   ; Patients with Cystic Fibrosis
37   FBIO      = FBIO_CF
38   KA        = LOG(2)/(TABS_CF/60)
39   KAEHC     = LOG(2)/(TAEHC_CF/60)
40
41   FCYF_CLR  = FCLR
42   FCYF_CLNR = FCLNR
43   FCYF_CLEX = FCLEX
44   FCYF_VSS  = FVSS
45
46   TFM_NOR   = TFM_NORCF
47   DFM_NOX   = DFM_NOXCF
48 ELSE
49   ; Healthy volunteers
50   FBIO      = FBIO_HV
51   KA        = LOG(2)/(TABS_HV/60)
52   KAEHC     = LOG(2)/(TAEHC_HV/60)
53
54   FCYF_CLR  = 1
55   FCYF_CLNR = 1
56   FCYF_CLEX = 1
57   FCYF_VSS  = 1
58
59   TFM_NOR   = TFM_NORHV
60   DFM_NOX   = DFM_NOXHV
61 ENDIF
62

```

Figure S3. code for the final model in SADAPT-TRAN format.

```

63 BOLUSF(1) = FBIO
64
65 FM_NOR      = 1/(1+EXP(-TFM_NOR))
66
67 TFM_NORNOX = DFM_NOX + TFM_NOR
68 FM_NORNOX  = 1/(1+EXP(-TFM_NORNOX))
69
70 FM_NOX2     = FM_NORNOX - FM_NOR
71 FM_NOX      = MAX(0,FM_NOX2) ; to improve robustness of code
72
73 TLAGH= TLAG/60
74
75 FWTCL = (FFM/53)**0.75
76 FWTV  = (FFM/53)
77
78 ; Elimination clearances
79 CLR_COV = FCYF_CLR * FWTCL * CLR
80 CLNR_COV = FCYF_CLNR * FWTCL * CLNR
81 CLgut_COV = FCYF_CLEX * FWTCL * CLgut
82 CLD_COV = FWTCL * CLD
83 V1_COV = FCYF_VSS * FWTV * V1
84 V2_COV = FCYF_VSS * FWTV * V2
85
86 $OUTPUT_ICS
87
88 $OUTPUT_EQN
89
90 IF (X(1).LT.0) X(1) = 0
91 IF (X(2).LT.0) X(2) = 0
92 IF (X(3).LT.0) X(3) = 0
93 IF (X(4).LT.0) X(4) = 0
94 IF (X(5).LT.0) X(5) = 0
95 IF (X(6).LT.0) X(6) = 0
96 IF (X(7).LT.0) X(7) = 0
97
98 C1 = X(2)/V1_COV ; Serum concentrations of pefloxacin (mg/L)
99
100 Y(1) = C1
101
102 Y(2) = 100*X(4)/400 ; fraction of dose excreted in urine as unchanged pefloxacin
103 Y(3) = 100*X(5)/400 ; fraction of dose excreted in urine as norfloxacin
104 Y(4) = 100*X(6)/400 ; fraction of dose excreted in urine as pefloxacin-N-oxide
105
106 ; Empty the bucket for the cumulative amount excreted into urine (=reset event)
107 IF (EVID.EQ.5) THEN
108     X(1) = 0
109     X(2) = 0
110     X(3) = 0
111     X(4) = 0
112     X(5) = 0
113     X(6) = 0
114     X(7) = 0
115 ENDIF
116
117 $VARMOD_EQN
118
119 V(1) = ( SDin + SDs1*Y(1) ) * ( SDin + SDs1*Y(1) )
120
121 V(2) = UPin * UPin
122 V(3) = URin * URin
123 V(4) = UXin * UXin
124
125 $POPMOD_EQN
126

```

Figure S3. code for the final model in SADAPT-TRAN format (continued).